Sight Sciences SEC filings document the company’s ophthalmic medical device business, segment operating results, governance, capital structure, and material events. Form 8-K filings report quarterly and annual financial results, investor presentation materials, and Regulation FD disclosures tied to the company’s Interventional Glaucoma and Interventional Dry Eye operations.
The filing record also includes definitive proxy materials for annual meeting matters, disclosures on executive officer changes and compensatory arrangements, material agreements such as lease amendments, and legal disclosures involving interventional glaucoma patents. These filings frame SGHT’s public reporting around product commercialization, intellectual property, corporate governance, risk factors, and shareholder voting matters.
Jeremy Hayden filed a Form 144 indicating an intent to sell 48,000 shares of common stock of SGHT through Fidelity Brokerage Services LLC on August 14, 2026, in connection with a stock option exercise on NASDAQ. The planned sale has an indicated aggregate market value of $395,878.84.
Over the prior three months, Hayden reported sales of SGHT common stock totaling 52,453 shares for aggregate proceeds of $389,080.31 across four transactions on July 6, August 11, 12, and 13, 2026.
SGHT-related securities holder filed a notice of intent to sell 2,500 shares of common stock, held at Fidelity Brokerage Services, with an indicated value of $20,762.50 and a planned sale date of August 13, 2026 on NASDAQ. The filing also notes that these 2,500 shares arise from restricted stock vesting on June 30, 2026 as compensation, and lists prior common stock sales over the past three months by Jeremy Hayden on July 6, 2026, August 11, 2026, and August 12, 2026.
A proposed sale of 16,302 Sight Sciences, Inc. (SGHT) common shares by former officer Jeremy Hayden is listed at an aggregate market value of $133,307.09, with an approximate sale date of August 12, 2026. The notice also lists Jeremy Hayden's prior sales: 12,733 shares on July 6, 2026, for gross proceeds of $70,132.10, and 20,918 shares on August 11, 2026, for gross proceeds of $165,878.62.
SGHT insider Jeremy Hayden filed to sell up to 20,918 shares of common stock through Fidelity Brokerage Services, with an estimated aggregate market value of $165,878.62, to be sold on or after August 11, 2026 on NASDAQ.
The shares relate to prior and scheduled restricted stock vesting events treated as compensation. In addition, Hayden reported having sold 12,733 shares of common stock for $70,132.10 on July 6, 2026 under Form 144’s “securities sold during the past 3 months” section.
Sight Sciences, Inc. appointed Kashif Rashid as Chief Legal Officer and Corporate Secretary effective August 10, 2026, succeeding Jeremy Hayden, who will step down on that date and stay through August 31, 2026 to assist with transition. Rashid brings extensive legal and corporate development experience from prior roles at Nevro Corp., Atara Biotherapeutics, St. Jude Medical and General Electric’s healthcare business.
Under his employment agreement, Rashid will receive an initial annual base salary of $450,000 and will be eligible for an annual cash bonus targeted at 50% of base salary. If terminated without cause or if he resigns for good reason, he is entitled to 12 months of base-salary severance, any earned but unpaid prior-year bonus, and up to 12 months of COBRA premium support, subject to specified conditions. He is also eligible for a restricted stock unit award valued at $1,400,000, vesting in four equal annual installments starting August 10, 2027, with the number of shares based on the grant-date closing price and capped at 280,000 shares. Hayden, subject to a separation agreement and release, will receive one year of base salary and up to one year of COBRA benefits.
Sight Sciences reported Q2 2026 revenue of $23.4 million, up 19.5% year over year, and first‑half revenue of $43.1 million. Gross margin improved to 91.4% in the quarter, supported by tariff refunds and higher average selling prices. Net loss narrowed to $4.4 million in Q2 and $17.4 million year‑to‑date.
Interventional Glaucoma contributed $20.7 million of Q2 revenue, while Interventional Dry Eye grew to $2.7 million as Medicare fee schedules for the TearCare procedure drove higher volume. Cash and cash equivalents were $79.8 million against $40.0 million of term loans at a 10.35% rate; operating cash outflow was $12.7 million for the first half. A Delaware federal court entered judgment awarding $55.4 million in patent damages and a 10% ongoing royalty on Hydrus Microstent revenue, though Alcon has appealed and two related USPTO ex parte reexaminations remain pending. Management believes existing liquidity will fund at least the next 12 months while it continues commercialization and R&D at reduced spending levels.
Sight Sciences reported strong Q2 2026 results, with revenue of $23.4 million, up 20% year-over-year, driven by 8% growth in Interventional Glaucoma to $20.7 million and a 704% surge in Interventional Dry Eye to $2.7 million. Gross margin was 91%, benefiting from $1.4 million of tariff refunds; excluding these, gross margin was 86%.
Total operating expenses fell 11% to $25.3 million and adjusted operating expenses declined 8% to $22.3 million. Net loss narrowed to $4.4 million, a 63% improvement, or $0.08 per share. Cash and cash equivalents were $79.8 million, with cash usage of $5.2 million including one-time items; excluding these, usage was $1.4 million.
Management raised 2026 guidance, now expecting revenue of $88 million to $92 million and adjusted operating expenses of $92 million to $94 million. The quarter also featured expanded payer coverage for both glaucoma and dry eye treatments and FDA 510(k) clearance for the OMNI Ultra Surgical System.
Sight Sciences Chief Legal Officer Jeremy B. Hayden reported selling 12,733 shares of common stock, with a weighted average price of $5.51 per share. According to the disclosure, these shares were sold solely to cover his tax liability arising from the vesting of restricted stock units.
After this tax-related sale, Hayden holds 357,037 shares tied to Sight Sciences, including 100,015 shares of common stock and 257,022 shares that are scheduled to be received as restricted stock units vest in the future. The transaction reflects routine tax withholding rather than a discretionary reduction in his overall stake.
Sight Sciences Chief Financial Officer James Rodberg reported an open-market sale of 6,902 shares of common stock on July 2, 2026 at a weighted average price of $5.36 per share, in transactions ranging from $5.19 to $5.46. According to the footnotes, these shares were sold to cover his tax liability arising from the vesting of restricted stock units. Following the sale, he beneficially owns 224,037 shares, including 55,200 shares of common stock and 168,837 shares that will be acquired upon future vesting and settlement of RSUs.
Sight Sciences, Inc. Chief Technology Officer David Badawi reported an open-market sale of 7,418 shares of common stock at a weighted average price of $5.508 per share. According to the footnotes, the sale was made to cover his tax liability arising from the vesting of restricted stock units.
After this transaction, Badawi directly held 1,982,872 shares of common stock and related equity, including 1,813,950 shares of common stock and 168,922 shares that will be acquired upon future vesting and settlement of unvested RSUs. The transaction represents a small portion of his overall equity position.